Evaxion Gestione

Criteri Gestione verificati 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Helen Tayton-Martin

Amministratore delegato

US$431.0k

Compenso totale

Percentuale dello stipendio del CEO	8.59%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	2.9yrs
Durata media del Consiglio di amministrazione	5.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Mar 11Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Aug 10

Evaxion Biotech announces new CEO as Lars Wegner resigns

Aug 02

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Helen Tayton-Martin rispetto agli utili di Evaxion?
Data	Compenso totale	Stipendio	Utili della società
Dec 31 2025	US$431k	US$37k	-US$8m

Compensazione vs Mercato: La retribuzione totale di Helen ($USD 430.97K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 631.78K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Helen con le performance aziendali.

AMMINISTRATORE DELEGATO

Helen Tayton-Martin (58 yo)

less than a year

Mandato

US$430,972

Compensazione

Dr. Helen Katrina Tayton-Martin, Ph D., MBA, was Chief Business & Strategy Officer of Adaptimmune Therapeutics plc from October 2022 to 2025. She is the Co-Founder of Adaptimmune Therapeutics plc and had b...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Helen Tayton-Martin	Chief Executive Officer	less than a year	US$430.97k	Nessun dato
Andreas Mattsson	Founder & Chief AI Officer	18.2yrs	US$364.00k	1.32% $ 389.0k
Thomas Schmidt	Chief Financial Officer	1.3yrs	US$376.00k	0.15% $ 45.5k
Birgitte Rono	Chief Scientific Officer	4.5yrs	US$402.00k	0.0088% $ 2.6k
Benjamin Wolthers	Vice President of Clinical Development	no data	Nessun dato	Nessun dato

2.9yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di EVAX è considerato esperto (durata media dell'incarico 2.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rajeev Surati	Member of Advisory Board	no data	Nessun dato	Nessun dato
Robert Palay	Member of Advisory Board	no data	Nessun dato	Nessun dato
Jeffrey Weber	Member of Advisory Board	no data	Nessun dato	Nessun dato
Soren Brunak	Member of Advisory Board	no data	Nessun dato	Nessun dato
Michael Washabaugh	Member of Advisory Board	no data	Nessun dato	Nessun dato
Thomas Wylonis	Member of Advisory Board	no data	Nessun dato	Nessun dato
Lars Holtug	Independent Director	4.8yrs	US$70.00k	0.062% $ 18.2k
Anthony Purcell	Member of Advisory Board	no data	Nessun dato	Nessun dato
Andrew Webber	Member of Advisory Board	no data	Nessun dato	Nessun dato
Marianne Sogaard	Independent Chairwoman of the Board	5.3yrs	US$196.00k	0.93% $ 272.0k
Roberto Pineda	Independent Director	8.2yrs	US$64.00k	0.28% $ 82.4k
Lars Wegner	Director	1.9yrs	US$54.00k	0.031% $ 9.1k

5.1yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EVAX sono considerati esperti (durata media dell'incarico 5.1 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/03/29 09:27
Prezzo dell'azione a fine giornata	2026/03/27 00:00
Utili	2025/12/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Evaxion A/S è coperta da 6 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Swayampakula Ramakanth	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Thomas Flaten	Lake Street Capital Markets, LLC

Evaxion Gestione

Criteri Gestione verificati 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Evaxion A/S, Annual General Meeting, Apr 16, 2026

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces CEO Changes

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Recent updates

Evaxion A/S, Annual General Meeting, Apr 16, 2026

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases

Evaxion A/S to Report Q3, 2026 Results on Nov 19, 2026

Evaxion A/S to Report Q3, 2025 Results on Nov 06, 2025

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma

Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting

Evaxion A/S to Report Q2, 2025 Results on Aug 14, 2025

Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025

Evaxion A/S Announces CEO Changes

Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion A/S to Report Q1, 2025 Results on May 27, 2025

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01

Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $4.48 million.

Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology™?

Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination

Evaxion Completes Dosing in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Establishes New AI-Derived Precision Cancer Vaccine Concept

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study